Disease landscape

EGFR Mutant Lung Cancer clinical trials

Get alerts when EGFR Mutant Lung Cancer trials change

4 active trials 0 recruiting 2 sponsors 2 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days

2026-08-12
Primary completion pushed: 2026-06-30 → 2027-06-30
Completion pushed: 2026-12-30 → 2027-12-30
NCT03392246 A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve… · Dana-Farber Cancer Institute · Phase 2

Active trials by phase

Phase 1
1
Phase 1/2
1
Phase 2
2

Active trials

NCT IDTitleSponsorStatusUpdated
Phase 2
NCT03392246 A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve… Dana-Farber Cancer Institute Active, Not Recruiting 2026-08-11
NCT03586453 Osimertinib In EGFR Mutant Lung Cancer Dana-Farber Cancer Institute Active, Not Recruiting 2026-04-29
Phase 1/2
NCT03122717 Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Dana-Farber Cancer Institute Active, Not Recruiting 2026-04-29
Phase 1
NCT03567642 A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With… Memorial Sloan Kettering Cancer Center Active, Not Recruiting 2026-07-06

Top sponsors by active trials in this area

Dana-Farber Cancer Institute (3) · Memorial Sloan Kettering Cancer Center (1)

Get alerts when EGFR Mutant Lung Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free